• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax.

作者信息

Lima Keli, Vicari Hugo Passos, Carlos Jorge Antonio Elias Godoy, da Silva Jean Carlos Lipreri, Figueiredo-Pontes Lorena Lobo de, Rego Eduardo Magalhães, Machado-Neto João Agostinho

机构信息

Institute of Biomedical Sciences, Universidade de Sao Paulo, Sao Paulo, SP, Brazil; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.

Institute of Biomedical Sciences, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.

出版信息

Hematol Transfus Cell Ther. 2022 Jan-Mar;44(1):124-127. doi: 10.1016/j.htct.2021.01.004. Epub 2021 Mar 13.

DOI:10.1016/j.htct.2021.01.004
PMID:33753045
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8885367/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cb3/8885367/563f6093fe5c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cb3/8885367/e9272090c463/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cb3/8885367/563f6093fe5c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cb3/8885367/e9272090c463/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cb3/8885367/563f6093fe5c/gr2.jpg

相似文献

1
Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax.奥巴托克斯可降低急性髓系白血病细胞系的细胞活力，且与它们对维奈托克的敏感性无关。
Hematol Transfus Cell Ther. 2022 Jan-Mar;44(1):124-127. doi: 10.1016/j.htct.2021.01.004. Epub 2021 Mar 13.
2
Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.维奈克拉协同沃沙罗汀增强急性髓系白血病细胞体外抗白血病活性。
Target Oncol. 2019 Jun;14(3):351-364. doi: 10.1007/s11523-019-00638-4.
3
Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).新型Bcl-2同源结构域3模拟物GX15-070（奥巴托克斯）的抗白血病活性机制
Cancer Res. 2008 May 1;68(9):3413-20. doi: 10.1158/0008-5472.CAN-07-1919.
4
The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia.HDAC 和 PI3K 双重抑制剂 CUDC-907 与 venetoclax 在急性髓系白血病的临床前模型中协同增强抗白血病活性。
Haematologica. 2021 May 1;106(5):1262-1277. doi: 10.3324/haematol.2019.233445.
5
Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.MDM2拮抗剂idasanutlin与Bcl-2抑制剂维奈托克在p53野生型急性髓系白血病模型中的卓越抗肿瘤活性。
J Hematol Oncol. 2016 Jun 28;9(1):50. doi: 10.1186/s13045-016-0280-3.
6
Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.通过共同靶向 MCL1 增强急性髓系白血病中的 venetoclax 活性。
Leukemia. 2018 Feb;32(2):303-312. doi: 10.1038/leu.2017.243. Epub 2017 Jul 28.
7
Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.阿比替尼与维奈托克联合应用通过 BTK 依赖性途径增强急性髓系白血病的抗白血病活性。
Mol Oncol. 2020 Oct;14(10):2560-2573. doi: 10.1002/1878-0261.12742. Epub 2020 Jul 3.
8
Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.Obatoclax 通过一种依赖 Bim 的过程抑制 Bcl-2 抗凋亡成员，从而增强索拉非尼诱导的人髓样白血病细胞凋亡。
Blood. 2012 Jun 21;119(25):6089-98. doi: 10.1182/blood-2011-09-378141. Epub 2012 Mar 23.
9
BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells.BH3模拟物 obatoclax增强人胰腺癌细胞中TRAIL介导的细胞凋亡。
Clin Cancer Res. 2009 Jan 1;15(1):150-9. doi: 10.1158/1078-0432.CCR-08-1575.
10
Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage.奥巴托克斯通过增强DNA损伤来增强阿糖胞苷对急性髓性白血病细胞的细胞毒性作用。
Mol Oncol. 2015 Feb;9(2):409-21. doi: 10.1016/j.molonc.2014.09.008. Epub 2014 Oct 2.

引用本文的文献

1
Inducing apoptosis in acute myeloid leukemia; mechanisms and limitations.诱导急性髓系白血病细胞凋亡：机制与局限性
Heliyon. 2024 Dec 19;11(1):e41355. doi: 10.1016/j.heliyon.2024.e41355. eCollection 2025 Jan 15.
2
Parallel single-cell metabolic analysis and extracellular vesicle profiling reveal vulnerabilities with prognostic significance in acute myeloid leukemia.平行单细胞代谢分析和细胞外囊泡分析揭示了急性髓系白血病中具有预后意义的脆弱性。
Nat Commun. 2024 Dec 30;15(1):10878. doi: 10.1038/s41467-024-55231-9.
3
Relationships of Prodiginins Mechanisms and Molecular Structures to their Antiproliferative Effects.

本文引用的文献

1
Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia.对患者样本进行综合分析，确定 venetoclax 疗效的生物标志物和急性髓系白血病的联合治疗策略。
Nat Cancer. 2020 Aug;1(8):826-839. doi: 10.1038/s43018-020-0103-x. Epub 2020 Aug 18.
2
Reversine exerts cytotoxic effects through multiple cell death mechanisms in acute lymphoblastic leukemia.雷维辛通过多种细胞死亡机制对急性淋巴细胞白血病发挥细胞毒性作用。
Cell Oncol (Dordr). 2020 Dec;43(6):1191-1201. doi: 10.1007/s13402-020-00551-3. Epub 2020 Aug 28.
3
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
原素类化合物的作用机制和分子结构与其抗增殖作用的关系。
Anticancer Agents Med Chem. 2024;24(19):1383-1395. doi: 10.2174/0118715206314212240805105735.
4
Design, Synthesis, and Potent Anticancer Activity of Novel Indole-Based Bcl-2 Inhibitors.新型吲哚基 Bcl-2 抑制剂的设计、合成及抗肿瘤活性研究。
Int J Mol Sci. 2023 Sep 28;24(19):14656. doi: 10.3390/ijms241914656.
阿扎胞苷和维奈托克治疗未经治急性髓系白血病。
N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971.
4
Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?维奈托克联合去甲基化药物或小剂量阿糖胞苷治疗急性髓系白血病：闪光的都是金子吗？
Blood Cancer J. 2020 Jan 28;10(1):10. doi: 10.1038/s41408-020-0281-x.
5
Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models.维奈托克联合 cobimetinib 靶向治疗急性髓系白血病模型中的 BCL2 和 MAPK 信号通路。
Haematologica. 2020 Mar;105(3):697-707. doi: 10.3324/haematol.2018.205534. Epub 2019 May 23.
6
A critical regulator of Bcl2 revealed by systematic transcript discovery of lncRNAs associated with T-cell differentiation.通过与 T 细胞分化相关的 lncRNAs 的系统转录本发现揭示 Bcl2 的关键调控因子。
Sci Rep. 2019 Mar 18;9(1):4707. doi: 10.1038/s41598-019-41247-5.
7
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.维奈托克联合地西他滨或阿扎胞苷治疗初治老年急性髓系白血病患者。
Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25.
8
A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.一种新型 MCL1 抑制剂与 Venetoclax 联合可挽救 Venetoclax 耐药的急性髓系白血病。
Cancer Discov. 2018 Dec;8(12):1566-1581. doi: 10.1158/2159-8290.CD-18-0140. Epub 2018 Sep 5.
9
Statins enhance efficacy of venetoclax in blood cancers.他汀类药物增强维奈托克在血液癌症中的疗效。
Sci Transl Med. 2018 Jun 13;10(445). doi: 10.1126/scitranslmed.aaq1240.
10
Non-apoptotic functions of BCL-2 family proteins.BCL-2 家族蛋白的非凋亡功能。
Cell Death Differ. 2017 Aug;24(8):1348-1358. doi: 10.1038/cdd.2017.22. Epub 2017 Feb 24.